Drug
Fxs0260
Fxs0260: highest development phase Phase 1, developed by Shanghai Fosun Pharmaceutical. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Shanghai Fosun Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| FXS0260 NCT07933666 | Phase 1 | Solid Tumor Refractory to Conventional Treatment |
Latest
No recent events.
Follow Fxs0260 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.